Explicit Assessment of Thromboembolic Risk and Prophylaxis for Medical Patients in Switzerland
Explicit Assessment of Thromboembolic Risk and Prophylaxis for Medical Patients in Switzerland (ESTIMATE): Evaluation of a Prediction Rule
Until now, no risk assessment model informing about the need of thromboprophylaxis in patients admitted for an acute medical event has been validated.
The goal of this project is to indirectly validate a model developed in Geneva by a non -interventional study involving the collection of patient characteristics during the hospitalization and a 3-month follow-up. These data will allow for the determination of the patient's risk, according to the Geneva model, and its validity, according the actual thrombo-embolic events, corrected for the thromboprophylaxis received.
The project is multicentric in Switzerland (5-10 centers) and should involve about 1000 patients.
First amendment (may 2011) : we have obtained the IRB approval for collecting data from patients who die during their hospital stay and for whom informed consent is not be possible to obtain.
연구 개요
상태
정황
연구 유형
등록 (실제)
연락처 및 위치
연구 장소
-
-
-
Baden, 스위스
- Kantonsspital
-
Bern, 스위스
- University Hospitals
-
Fribourg, 스위스
- Cantonal Hospital
-
Geneva, 스위스
- University Hospitals
-
Lüzern, 스위스
- Kantonsspital
-
St. Gallen, 스위스
- Cantonal Hospital
-
Zürich, 스위스
- University Hospital
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
샘플링 방법
연구 인구
설명
Inclusion Criteria:
- Patients admitted (minimal stay >24 hours) to medical hospital wards
- Age ≥18 years
- Ability to give an informed consent, as informed by the physicians in charge of the patient
Exclusion Criteria:
- Patients admitted to non-medical hospital wards
- Patients with therapeutic anticoagulation at hospital admission
- Patients admitted for a disease requiring therapeutic anticoagulation (MTE or other)
- Patients unable to give an informed consent, as informed by the physicians in charge of the patient
- Patients without signed informed consent
- Patients already included in this study
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
코호트 및 개입
그룹/코호트 |
|---|
|
hospitalization >24 hours
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
relationship between the combined rate of fatal and non-fatal symptomatic venous thromboembolism and bleeding events and the calculated risk score at 90 days after hospital admission
기간: 90 days
|
evaluation of the relationship between the combined rate of fatal and non-fatal symptomatic venous thromboembolism and bleeding events at 90 days after hospital admission on one hand, and the calculated risk score provided by the Geneva Risk Assessment Models (RAM) at hospital admission on the other hand
|
90 days
|
공동 작업자 및 조사자
협력자
수사관
- 수석 연구원: Mathieu R Nendaz, Dr, General Internal Medicine Division, University Hospitals of Geneva
간행물 및 유용한 링크
일반 간행물
- Chopard P, Spirk D, Bounameaux H. Identifying acutely ill medical patients requiring thromboprophylaxis. J Thromb Haemost. 2006 Apr;4(4):915-6. doi: 10.1111/j.1538-7836.2006.01818.x. No abstract available.
- Nendaz M, Spirk D, Kucher N, Aujesky D, Hayoz D, Beer JH, Husmann M, Frauchiger B, Korte W, Wuillemin WA, Jager K, Righini M, Bounameaux H. Multicentre validation of the Geneva Risk Score for hospitalised medical patients at risk of venous thromboembolism. Explicit ASsessment of Thromboembolic RIsk and Prophylaxis for Medical PATients in SwitzErland (ESTIMATE). Thromb Haemost. 2014 Mar 3;111(3):531-8. doi: 10.1160/TH13-05-0427. Epub 2013 Nov 14.
- Spirk D, Nendaz M, Aujesky D, Hayoz D, Beer JH, Husmann M, Frauchiger B, Korte W, Wuillemin WA, Righini M, Bounameaux H, Kucher N. Predictors of thromboprophylaxis in hospitalised medical patients. Explicit ASsessment of Thromboembolic RIsk and Prophylaxis for Medical PATients in SwitzErland (ESTIMATE). Thromb Haemost. 2015 May;113(5):1127-34. doi: 10.1160/TH14-06-0525. Epub 2015 Jan 22.
연구 기록 날짜
연구 주요 날짜
연구 시작
기본 완료 (실제)
연구 완료 (실제)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (추정)
연구 기록 업데이트
마지막 업데이트 게시됨 (추정)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .
정맥혈전색전증에 대한 임상 시험
-
Beijing Friendship Hospital알려지지 않은대장암 환자에서 Perioperiative Venous Thromboembolism(VTE)의 발생률
-
University Hospital, Strasbourg, France완전한
-
Medical University Innsbruck완전한급성 신장 손상 | 비판적으로 아프다 | 신장 대체 요법 | 지속적 신대체 요법 | 지속적인 Veno-Venous Hemofiltration | 교체액 | 포실륨 | 비포질 | 항응고제 | 지역 구연산염 항응고제오스트리아